Dr. Ken Fujise, a physician-scientist, is Director, Division of Cardiology and Professor of Medicine and of Biochemistry and Molecular Biology, at University of Texas Medical Branch, Galveston, Texas. He is the holder of John Sealy Centennial Chair in Medicine. His laboratory has been supported by grants from the National Institutes of Health (NIH), American Heart Association (AHA), and others. He is a recipient of Scientist Development Award (AHA), Mentored Clinical Scientist Development Award (K08, NIH), and Established Investigator Award (AHA). Dr. Fujise earned his MD from Kyoto University, School of Medicine. His internship and junior residency was at Metropolitan Hospital Center (New York Medical College) and senior residency and general cardiology fellowship at Thomas Killip MD Division of Cardiology at Beth Israel Medical Center (Mt. Sinai School of Medicine). Dr. Fujise’s research fellowship was at the Institute of Molecular Medicine for the Prevention and Treatment of Human Diseases (Director: Ferid Murad, MD, PhD). His interventional cardiology training was at University of Texas-Houston and Memorial Hermann Hospital. Dr. Fujise’s research has focused on fortilin. His laboratory was the first to report that fortilin possesses anti-apoptotic activity. It was also the first to report that fortilin and MCL1, a Bcl-2 family member anti-apoptotic molecule. The laboratory has also shown that fortilin interacts with p53, a tumor suppressor protein, and prevent p53 from transcriptionally activating its target genes such as Bax and Noxa. His laboratory continues to characterize fortilin with strong intention to bring the discoveries from bench to bedside, utilizing cellular, animal, and translational approaches.
Biography Updated on 4 March 2012